Linrodostat

Cat. No.: HY-101560

CAS No.: 1923833-60-6

Molecular Formula: $C_{24}H_{24}ClFN_2O$

Molecular Weight: 410.91

Target: Indoleamine 2,3-Dioxygenase (IDO)

Pathway: Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (121.68 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.4336 mL	12.1681 mL	24.3362 mL
	5 mM	0.4867 mL	2.4336 mL	4.8672 mL
	10 mM	0.2434 mL	1.2168 mL	2.4336 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline
   Solubility: 2.5 mg/mL (6.08 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (6.08 mM); Suspended solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (5.06 mM); Clear solution
4. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.08 mg/mL (5.06 mM); Suspended solution; Need ultrasonic
5. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.06 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Linrodostat (BMS-986205) is a selective and irreversible indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with an IC_{50} value of 1.1 nM in IDO1-HEK293 cells. Linrodostat is well tolerated with potent pharmacodynamic activity in advanced cancers[1][2].

IC_{50} & Target	IDO1 1.1 nM (IC_{50})
In Vitro	Linrodostat (0.01-100 μM; 72 hours; SKOV-3 and Jurkat clone E6-1 cells) treatment reduces the number of viable cells compared with the non-treated control. Linrodostat also induces cell death at much lower concentrations and its IC_{50} is 6.3 μM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay[1]

Cell Line:	SKOV-3 and Jurkat clone E6-1 cells
Concentration:	0.01-100 μM
Incubation Time:	72 hours
Result:	Reduced the number of viable cells compared with the non-treated controland induced cell death at much lower concentrations.

CUSTOMER VALIDATION

- Immunity. 2021 Sep 28;S1074-7613(21)00390-3.
- Cell Death Differ. 2021 Feb;28(2):715-729.
- SSRN. 2023 Dec 1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Richards T, et al. Cell based functional assays for IDO1 inhibitor screening and characterization. Oncotarget. 2018 Jul 20;9(56):30814-30820.

[2]. Lillian L. Siu, et al. Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial. AACR; Cancer Res. 2017; 77 (13 Suppl): Abstract nr CT116.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA